MedTrace Logo

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

NCT06314659 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2024-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months old.

Conditions

  • Healthy Population

Interventions

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)

Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)

Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)

Performed booster immunization at 18 months of age.

Sponsors & Collaborators

  • Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Lin Du · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
5 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314659 on ClinicalTrials.gov